propofol has been researched along with Brain Disorders in 22 studies
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.
propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.
Excerpt | Relevance | Reference |
---|---|---|
"The increment of GABAergic inhibitory activity, the reduction of metabolic rate and oxygen consumption induced by propofol on the neuronal components of brain structures, and its antioxidant potential have supported the possible beneficial effects of this drug against brain damage elicited by cerebral ischemia." | 7.69 | Effects of propofol on alterations of multineuronal activity of limbic and mesencephalic structures and neurological deficit elicited by acute global cerebral ischemia. ( Antonio-Ocampo, A; Cervantes, M; Chávez-Carrillo, I; Contreras-Gomez, A; Ruelas, R, 1995) |
"We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
"The increment of GABAergic inhibitory activity, the reduction of metabolic rate and oxygen consumption induced by propofol on the neuronal components of brain structures, and its antioxidant potential have supported the possible beneficial effects of this drug against brain damage elicited by cerebral ischemia." | 3.69 | Effects of propofol on alterations of multineuronal activity of limbic and mesencephalic structures and neurological deficit elicited by acute global cerebral ischemia. ( Antonio-Ocampo, A; Cervantes, M; Chávez-Carrillo, I; Contreras-Gomez, A; Ruelas, R, 1995) |
"This study compares the effects of propofol and fentanyl/N2O on spontaneous brain electrical activity, neurologic outcome, and neuronal damage due to incomplete cerebral ischemia in rats." | 3.68 | The effects of propofol on brain electrical activity, neurologic outcome, and neuronal damage following incomplete ischemia in rats. ( Albrecht, RF; Hoffman, WE; Kochs, E; Schulte am Esch, J; Thomas, C; Werner, C, 1992) |
"Propofol was added during the OGD phase of the model." | 1.35 | Propofol inhibits aquaporin 4 expression through a protein kinase C-dependent pathway in an astrocyte model of cerebral ischemia/reoxygenation. ( Pan, CF; Xiong, XX; Zheng, YY; Zhu, SM, 2009) |
"Propofol has been shown to protect against neuronal damage induced by brain ischaemia in small animal models." | 1.33 | A moderate dose of propofol and rapidly induced mild hypothermia with extracorporeal lung and heart assist (ECLHA) improve the neurological outcome after prolonged cardiac arrest in dogs. ( Ichinose, K; Okamoto, T; Sugita, M; Taguchi, H; Takeya, M; Tanimoto, H; Tashiro, M; Terasaki, H, 2006) |
"Propofol is an intravenous anesthetic agent with a short half-life allowing rapid recovery; it has cerebral hemodynamic effects similar to those of thiopental." | 1.29 | [Use of propofol in intracranial surgery in 83 consecutive patients]. ( Borgeat, A; Gaggero, G; Ravussin, P; Wilder-Smith, O, 1994) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (4.55) | 18.7374 |
1990's | 9 (40.91) | 18.2507 |
2000's | 8 (36.36) | 29.6817 |
2010's | 2 (9.09) | 24.3611 |
2020's | 2 (9.09) | 2.80 |
Authors | Studies |
---|---|
Umaba, C | 1 |
Mineharu, Y | 1 |
Liang, N | 1 |
Mizota, T | 1 |
Yamawaki, R | 1 |
Ueda, M | 1 |
Yamao, Y | 1 |
Nankaku, M | 1 |
Miyamoto, S | 1 |
Matsuda, S | 1 |
Inadomi, H | 1 |
Arakawa, Y | 1 |
Wu, M | 1 |
Yin, X | 1 |
Chen, M | 1 |
Liu, Y | 1 |
Zhang, X | 1 |
Li, T | 1 |
Long, Y | 1 |
Wu, X | 1 |
Pu, L | 1 |
Zhang, M | 1 |
Hu, Z | 1 |
Ye, L | 1 |
Villalba Martínez, G | 1 |
Fernández-Candil, JL | 1 |
Vivanco-Hidalgo, RM | 1 |
Pacreu Terradas, S | 1 |
León Jorba, A | 1 |
Arroyo Pérez, R | 1 |
Zhao, CH | 1 |
Li, GH | 1 |
Wang, Q | 1 |
Zhao, B | 1 |
Wang, ZB | 1 |
Morota, S | 1 |
Månsson, R | 1 |
Hansson, MJ | 1 |
Kasuya, K | 1 |
Shimazu, M | 1 |
Hasegawa, E | 1 |
Yanagi, S | 1 |
Omi, A | 1 |
Uchino, H | 1 |
Elmér, E | 1 |
Zhu, SM | 1 |
Xiong, XX | 1 |
Zheng, YY | 1 |
Pan, CF | 1 |
Iwata, T | 1 |
Inoue, S | 1 |
Kawaguchi, M | 1 |
Takahashi, M | 1 |
Sakamoto, T | 1 |
Kitaguchi, K | 1 |
Furuya, H | 1 |
Sakaki, T | 1 |
Saito, S | 1 |
Kadoi, Y | 1 |
Nihishara, F | 1 |
Aso, C | 1 |
Goto, F | 1 |
Schmitz, B | 1 |
Nimsky, C | 1 |
Wendel, G | 1 |
Wienerl, J | 1 |
Ganslandt, O | 1 |
Jacobi, K | 1 |
Fahlbusch, R | 1 |
Schüttler, J | 1 |
Ichinose, K | 1 |
Okamoto, T | 1 |
Tanimoto, H | 1 |
Taguchi, H | 1 |
Tashiro, M | 1 |
Sugita, M | 1 |
Takeya, M | 1 |
Terasaki, H | 1 |
Ikeda, Y | 1 |
Fudickar, A | 1 |
Tonner, PH | 1 |
Mihaljovic, Z | 1 |
Dellien, C | 1 |
Weiler, N | 1 |
Scholz, J | 1 |
Bein, B | 1 |
Newman, MF | 2 |
Murkin, JM | 2 |
Roach, G | 1 |
Croughwell, ND | 1 |
White, WD | 1 |
Clements, FM | 1 |
Reves, JG | 1 |
Gaggero, G | 1 |
Ravussin, P | 1 |
Borgeat, A | 1 |
Wilder-Smith, O | 1 |
Cervantes, M | 1 |
Ruelas, R | 1 |
Chávez-Carrillo, I | 1 |
Contreras-Gomez, A | 1 |
Antonio-Ocampo, A | 1 |
Roach, GW | 1 |
Martzke, J | 1 |
Ruskin, A | 1 |
Li, J | 1 |
Guo, A | 1 |
Wisniewski, A | 1 |
Mangano, DT | 1 |
Gritsaenko, IuM | 1 |
Kochs, E | 1 |
Hoffman, WE | 1 |
Werner, C | 1 |
Thomas, C | 1 |
Albrecht, RF | 1 |
Schulte am Esch, J | 1 |
Merlo, F | 1 |
Demo, P | 1 |
Lacquaniti, L | 1 |
Tricarico, L | 1 |
Faccin, G | 1 |
Irone, M | 1 |
Bone, ME | 1 |
Bristow, A | 1 |
Mele, D | 1 |
Consoletti, L | 1 |
Lattanzio, A | 1 |
Carrillo, E | 1 |
Mazzarella, B | 1 |
Mastronardi, P | 1 |
Cafiero, T | 1 |
Gargiulo, G | 1 |
Frangiosa, A | 1 |
Stella, L | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
5 trials available for propofol and Brain Disorders
Article | Year |
---|---|
Effects of propofol on intracranial pressure and prognosis in patients with severe brain diseases undergoing endotracheal suctioning.
Topics: Adult; Brain Diseases; Female; Glasgow Outcome Scale; Humans; Hypnotics and Sedatives; Intracranial | 2020 |
Comparison of the effects of sevoflurane and propofol on cooling and rewarming during deliberate mild hypothermia for neurosurgery.
Topics: Adult; Aged; Analysis of Variance; Anesthesia; Anesthetics, Inhalation; Anesthetics, Intravenous; Bl | 2003 |
End-tidal carbon dioxide monitoring stabilized hemodynamic changes during ECT.
Topics: Adult; Aged; Anesthetics, Intravenous; Brain; Brain Diseases; Carbon Dioxide; Electroconvulsive Ther | 2003 |
Cerebral physiologic effects of burst suppression doses of propofol during nonpulsatile cardiopulmonary bypass. CNS Subgroup of McSPI.
Topics: Aged; Body Temperature; Brain; Brain Diseases; Cardiopulmonary Bypass; Dose-Response Relationship, D | 1995 |
Ineffectiveness of burst suppression therapy in mitigating perioperative cerebrovascular dysfunction. Multicenter Study of Perioperative Ischemia (McSPI) Research Group.
Topics: Adult; Aged; Animals; Brain Diseases; Electroencephalography; Female; Heart Valves; Hemodynamics; Hu | 1999 |
17 other studies available for propofol and Brain Disorders
Article | Year |
---|---|
Intraoperative hand strength as an indicator of consciousness during awake craniotomy: a prospective, observational study.
Topics: Adult; Aged; Anesthetics, Intravenous; Brain Diseases; Consciousness; Craniotomy; Female; Hand; Hand | 2022 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
Mechanisms of propofol attenuation of ketamine-induced neonatal brain injury.
Topics: Anesthetics, Intravenous; Animals; Apoptosis; Brain Diseases; Cognition Disorders; Disease Models, A | 2016 |
Evaluation of putative inhibitors of mitochondrial permeability transition for brain disorders--specificity vs. toxicity.
Topics: Amino Acid Isomerases; Animals; Boron Compounds; Brain; Brain Diseases; Calcium; Cyclophilins; Dose- | 2009 |
Propofol inhibits aquaporin 4 expression through a protein kinase C-dependent pathway in an astrocyte model of cerebral ischemia/reoxygenation.
Topics: Animals; Animals, Newborn; Aquaporin 4; Astrocytes; Brain Diseases; Brain Edema; Cell Hypoxia; Cell | 2009 |
Anesthesia during high-field intraoperative magnetic resonance imaging experience with 80 consecutive cases.
Topics: Adolescent; Adult; Aged; Androstanols; Anesthesia, Intravenous; Anesthetics, Intravenous; Brain Dise | 2003 |
A moderate dose of propofol and rapidly induced mild hypothermia with extracorporeal lung and heart assist (ECLHA) improve the neurological outcome after prolonged cardiac arrest in dogs.
Topics: Anesthetics, Intravenous; Animals; Brain Diseases; Dogs; Female; Heart Arrest; Heart-Assist Devices; | 2006 |
[Electron spin resonance method and brain diseases].
Topics: Animals; Antipyrine; Brain Diseases; Edaravone; Electron Spin Resonance Spectroscopy; Free Radical S | 2006 |
Suggested beginning of propofol infusion syndrome in an adult patient without lactacidosis: a case report.
Topics: Acidosis, Lactic; Adult; Anesthesia, Intravenous; Anesthetics, Intravenous; Brain Diseases; Creatine | 2008 |
[Use of propofol in intracranial surgery in 83 consecutive patients].
Topics: Adult; Aged; Anesthesia, Intravenous; Brain Diseases; Brain Neoplasms; Female; Hemodynamics; Humans; | 1994 |
Effects of propofol on alterations of multineuronal activity of limbic and mesencephalic structures and neurological deficit elicited by acute global cerebral ischemia.
Topics: Acute Disease; Animals; Antioxidants; Brain Diseases; Brain Ischemia; Cats; Limbic System; Mesenceph | 1995 |
[Hormonal, immune and metabolic status in intraoperative injury in the course of electrical stimulation with propofol].
Topics: Adult; Anesthetics, Intravenous; Brain; Brain Diseases; Electric Stimulation; Hemodynamics; Humans; | 1999 |
The effects of propofol on brain electrical activity, neurologic outcome, and neuronal damage following incomplete ischemia in rats.
Topics: Animals; Brain; Brain Damage, Chronic; Brain Diseases; Brain Ischemia; Depression, Chemical; Electro | 1992 |
[Propofol in single bolus for treatment of elevated intracranial hypertension].
Topics: Adolescent; Adult; Blood Pressure; Brain Diseases; Cerebrovascular Circulation; Female; Humans; Intr | 1991 |
Total intravenous anaesthesia in stereotactic surgery--one year's clinical experience.
Topics: Adolescent; Adult; Anesthesia, Intravenous; Blood Pressure; Brain Diseases; Catheterization, Periphe | 1991 |
[Total intravenous anesthesia with propofol-fentanyl in patients undergoing neurosurgery].
Topics: Adult; Aged; Anesthesia, Intravenous; Brain Diseases; Electroencephalography; Electromyography; Fema | 1990 |
[Effects of propofol (diprivan) on intracranial pressure. Preliminary controlled study versus thiopentone].
Topics: Anesthesia, Intravenous; Anesthetics; Brain Diseases; Drug Administration Schedule; Female; Hemodyna | 1987 |